IceCure Secures Japanese Patent for Controlled Cryoablation By Investing.com

© IceCure Medical Promotion

CAESAREA, Israel – IceCure Medical Ltd. (NASDAQ:ICCM), a company specializing in cryoablation technology, announced today that it has received a notice of approval from the Japan Patent Office for its patent entitled “Cryogenic Fluid Flow Control.”

The patent, expected to be effective until 2042, is part of IceCure’s strategy to improve the accuracy and efficiency of cryoablation procedures, a minimally invasive method of destroying tumors through freezing.

The ProSense® system developed by IceCure utilizes liquid nitrogen to freeze and eradicate both benign and malignant tumors, including those found in the breast, kidney, lung, and liver. The system is designed to be easy to use and transport, enabling a rapid office-based procedure for breast tumors, potentially reducing patient recovery time, pain, and surgical risk.

The newly granted patent focuses on modulating cryogenic fluid flow based on sensor data to ensure that the desired temperature is consistently maintained at the catheter and probe tips during cryoablation.

This control is important for the safety of surrounding tissue and the overall success of the procedure. Advanced features of the system include support for navigation and mapping within the patient’s body, which could expand the potential applications of the technology.

Eyal Shamir, CEO of IceCure, expressed confidence that the new patent will play an important role in advancing the field of cryoablation by allowing for more accurate exploration and mapping, and could lead to broader clinical application. IceCure’s presence in the Japanese market is expected to be further strengthened through its partnership with Japanese distributor Terumo.

The patent is still awaiting approval in other key markets, including the European Union and the United States. IceCure’s intellectual property portfolio currently includes 42 issued and granted patents, reflecting its commitment to innovation in cryoablation technology.

Information in this article is based on a press release from IceCure Medical.

This article was sponsored by AI and reviewed by an editor. Please see our T&Cs for more details.